Modular Medical's Tubeless Patch Insulin Pump Pivot Receives FDA 510(k) Clearance

April 9, 2026Modular Medical（Nasdaq: MODD）Announced, itsTubeless Patch Pump Pivot Receives FDA 510(k) Clearance, Initial User Deliveries Planned for End of Q2 2026.This is the company's second approved product following its previous generation product MODD1 (which received FDA approval about a year ago).

# Product Positioning: Targeting the "Almost Need a Pump" Population

Pivot's target user group is defined by Modular Medical as "almost-pumpers" – adult patients with type 1 or type 2 diabetes who are still using multiple daily injections (MDI) but have concerns about traditional insulin pumps. Industry data cited by the company shows that approximately 70% of insulin-dependent adults still use MDI, with complexity, bulkiness, and cost (summarized by the company as the "3Cs") being the main barriers.

The core design difference of Pivot lies in its two-part detachable structure:The pump can be detached from the patch base (for scenarios such as bathing, exercising, etc.), and it comes with a 3 mL replaceable medication reservoir and disposable batteries (no charging required).The pump body is equipped with a quick high-dose button, allowing for daily operation without a controller; it also supports smartphone connectivity for high-dose administration and monitoring. The company positions this design as"Reusable + Consumables" Architecture——Separate electronic components from consumable parts to control long-term usage costs.

The initial production capacity disclosed by the company can support approximately 6,000 users, and it stated that the manufacturing platform has the capability for low-cost rapid expansion. Regarding the software roadmap, features such as variable large dosing, improved alarm functions, and ACE/AID (Automated Insulin Delivery) compatibility are under development, but no specific timeline has been disclosed. CE Mark certification is expected to be completed between Q4 2026 and Q1 2027.

# Competitive Landscape: Insulet Dominates, Multiple Giants Line Up to Enter

The tubeless patch pump market is currently dominated by Insulet's Omnipod series.Insulet's Total Revenue for Fiscal Year 2025 Reached $2.7 Billion (Up Approximately 31% Year-over-Year), with Over 600,000 Active Global Omnipod Users; Ranked First in New Customer Starts and AID Prescriptions in the U.S.Omnipod 5 is currently the only tubeless AID system approved for both Type 1 and Type 2 diabetes indications. Insulet has announced that Omnipod 6 will be launched in 2027, featuring an adaptive learning algorithm.

Pivot has entered a window period with密集的竞争对手 but no products have been launched yet. Medtronic, Tandem, and Beta Bionics are all developing patch pump products, but none have been approved:

Comparison of Competitor Progress in Tubeless/Patch Insulin Pumps

Pivot occupies a relatively unique position in this landscape: it is the second tubeless patch pump to receive FDA approval after Omnipod, but currently lacks AID (Automated Insulin Delivery) functionality — which is becoming a standard feature in this market. Omnipod 5 has already achieved closed-loop automated insulin delivery, while Medtronic's MiniMed 780G, Tandem's Control-IQ, and Beta Bionics' iLet all have AID products available for sale (albeit in tubed pump form). Pivot currently only supports manual bolus doses and basal rates, with AID compatibility still in the roadmap phase.

# Corporate Background and Capital Status

Modular Medical was founded by Paul DiPerna, who previously established Tandem Diabetes Care in 2005 and designed the t:slim insulin pump. The company is currently in the pre-commercialization stage and has no revenue. EBITDA for the past 12 months was negative $25.3 million.

In terms of capital operations, the company completed a public offering of $4.68 million in December 2025, and a $12 million public offering at a premium in March 2026. A 1:30 reverse stock split was implemented on March 31, 2026. Additionally, CEO Jeb Besser provided the company with a $350,000 line of credit at an annual interest rate of 12%. As of April 9, the company's market value was approximately $23.8 million.

# Key Variables for Commercialization

Pivot’s approval has cleared regulatory hurdles, but there are still multiple unverified steps from 510(k) to actual commercialization: payer coverage (the commercial insurance coverage for insulin pumps in the U.S. and Medicare Part D policies directly determine patients’ ability to pay), the willingness of endocrinologists and diabetes educators to prescribe, and the impact of lacking AID functionality on conversion rates. The company claims a $3 billion "almost-pumper" market size based on its own estimates, with the actual reachable share depending on pricing strategy — whether Pivot's "reusable + consumables" cost structure can find a price range between Omnipod's fully disposable model and traditional tubed pumps remains undisclosed as pricing information is not yet available.

Initial capacity supports a scale of 6,000 users, compared to Insulet's installed base of over 600,000 active users, indicating that Modular Medical is still in the small-scale validation phase. Whether the company can complete early user accumulation before the launch of AID functionality, leveraging its differentiated positioning of "simplicity + low cost + detachability," will be its core challenge in the second half of 2026.